### General
Comment to include a footnote on all instances of interferon alfa-2b due to product discontinuation: “Peginterferon alfa-2a may be substituted for other interferon preparations”

Based on the discussion, the panel consensus was to add the proposed footnote, “Peginterferon alfa-2a may be substituted for other interferon preparations” to all instances of interferon alfa-2b.

<table>
<thead>
<tr>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
</tr>
<tr>
<td>16</td>
</tr>
</tbody>
</table>

### TCEL-B
**External request**
Submission request from Verastem Oncology to consider the following:

- **TCEL-B 2 of 5**: PTCL-NOS, EATL; MEITL; Nodal PTCL, TFH; FTCL - Add duvelisib as a preferred regimen, single agents under “Second-line Therapy (with intention to proceed to transplant) and Subsequent Therapy” and under “Second-line Therapy (no intention to transplant) and Subsequent Therapy”

- **TCEL-B 3 of 5**: AITL - Add duvelisib as a preferred regimen, single agents under “Second-line Therapy (with intention to proceed to transplant) and Subsequent Therapy” and under “Second-line Therapy (no intention to transplant) and Subsequent Therapy”

- **TCEL-B 4 of 5**: ALCL - Add duvelisib as a preferred regimen, single agents under “Second-line Therapy (with intention to proceed to transplant) and Subsequent Therapy” and under “Second-line Therapy (no intention to transplant) and Subsequent Therapy”

Based on the review of data and discussion, the panel consensus did not support the inclusion of duvelisib as an option due to limited available data.

See Submissions for references.

<table>
<thead>
<tr>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
</tr>
<tr>
<td>0</td>
</tr>
</tbody>
</table>
### NKTL-B
**Internal request**
Consider the inclusion of DDGP (dexamethasone, cisplatin, gemcitabine, pegasparagase) as an induction therapy option for extranodal NK/T-Cell Lymphoma, nasal type.

**Panel Discussion/References**
Based on the noted reference and discussion, the panel consensus was to include DDGP as an induction therapy option for extranodal NK/T-Cell Lymphoma, nasal type. This is a category 2A, preferred recommendation.


**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>0</td>
<td>0</td>
<td>12</td>
</tr>
</tbody>
</table>

---

### TCEL-B
**External request**
Submission request from Verastem Oncology to consider the following:
- TCEL-B 2 of 5: PTCL NOS, EATL; MEITL; Nodal PTCL, TFH; FTCL - Add duvelisib plus romidepsin as a preferred regimen, combination regimen under “Second-line Therapy (with intention to proceed to transplant and no intention to transplant) and Subsequent Therapy”
- TCEL-B 3 of 5: AITL - Add duvelisib plus romidepsin as a preferred regimen, combination regimen under “Second-line Therapy (with intention to proceed to transplant and no intention to transplant) and Subsequent Therapy”
- TCEL-B 4 of 5: ALCL - Add duvelisib plus romidepsin as a preferred regimen, combination regimen under “Second-line Therapy (with intention to proceed to transplant and no intention to transplant) and Subsequent Therapy”

Based on the review of data and discussion, the panel consensus did not support the inclusion of duvelisib + romidepsin as an option due to limited available data.

See Submissions for references.